News

Vertex posts additional trial data for type 1 diabetes therapy
Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...
Zacks Investment Research on MSN22h
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.68% at $440.87. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow gained 0.08% ...